TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Geriatrician Nathaniel Chin argues that persistent subjective cognitive decline can be a reason to establish a thorough cognitive baseline and monitor changes, even when test results are in the normal range. It does not itself diagnose Alzheimer’s disease, and the supplied report excerpt does not establish that biomarker testing or treatment is appropriate for everyone with these concerns.
Geriatrician Nathaniel Chin says persistent concerns about memory or thinking deserve closer evaluation even when comprehensive cognitive testing falls within the normal range, describing subjective cognitive decline as a possible early opportunity to monitor changes and investigate Alzheimer’s risk. In a Being Patient article published October 27, 2026, Chin emphasizes that subjective cognitive decline is not an Alzheimer’s diagnosis and that several other conditions can affect how sharp a person feels.
Subjective cognitive decline (SCD) refers to a person’s persistent sense that their cognitive abilities have worsened compared with their earlier abilities, despite testing that does not identify objective impairment. Chin, a memory-care physician at UW Health and an associate professor at the University of Wisconsin–Madison, says a normal test result should not automatically end the evaluation.
He distinguishes a brief screening test, which typically takes five to 15 minutes and samples a limited range of abilities, from a comprehensive evaluation that generally takes an hour or more. A fuller assessment can examine memory, language, attention and executive functions such as planning and organizing. Chin also cautions that tests usually compare people with others of similar age, rather than directly with their own past performance. Someone whose abilities have declined from a high starting point may still score within the average range.
Chin recommends considering a detailed baseline, possible contributors to the reported changes, observations from a person who knows the patient and repeat testing over time. The article also discusses blood tests, cerebrospinal fluid testing and amyloid PET as ways to investigate Alzheimer’s-related biology in selected patients. The provided report excerpt does not specify who should receive these tests, their results, or treatment recommendations.
Why Normal Scores May Not End Follow-Up
The issue matters because a single normal score can be reassuring without showing whether a person has changed from their own previous level. A repeated assessment may help clinicians distinguish a stable concern from a consistent decline, while also creating a point of comparison for future visits. Chin’s argument is that waiting until a score falls into an impaired range may miss an opportunity to understand a change earlier.
That does not mean every memory lapse signals disease or that earlier testing will prevent Alzheimer’s. SCD describes a reported experience, not its cause. The practical implication is more measured: persistent changes can prompt a conversation with a clinician about a fuller evaluation, potentially reversible or treatable contributors, and whether follow-up is warranted. For patients and families, this may replace a simple “normal” result with a clearer plan for monitoring.
Popular right now
Vitamix 5200 Professional-Grade Blender, 64 oz. Container, Black
KitchenAid Classic Series 4.5 Quart Tilt-Head Stand Mixer (K45SS), Onyx Black
Breville BES870XL Barista Express Espresso Machine, Brushed Stainless Steel
As an affiliate, we earn on qualifying purchases.
How Clinicians Interpret SCD Features
Chin describes “SCD plus,” a set of features developed by psychiatrist Frank Jessen and colleagues in the international Subjective Cognitive Decline Initiative. The features include a memory-focused change, onset within the previous five years, onset at age 60 or older, concern about the change, persistence, seeking medical help and confirmation from someone who knows the person well.
These features are not proof of Alzheimer’s disease. Chin says that several together may support closer attention. His comparison is between a person with intermittent word-finding concerns over 15 years, often linked to poor sleep or stress, and someone in their 60s with a more recent, persistent memory change noticed by a spouse. Both might test within normal limits, but the pattern and outside observations differ.
The article also names sleep problems, medications, depression or anxiety, illness, vascular disease, hearing loss, stress and normal aging as possible influences on perceived cognition. That range of explanations is why SCD requires evaluation rather than assumption.
What SCD Cannot Establish
SCD does not establish that Alzheimer’s disease is present, and the features grouped under SCD plus do not prove it. The supplied article excerpt ends as it introduces blood biomarkers, cerebrospinal fluid testing and amyloid PET; it does not provide further detail about their accuracy, risks, costs, availability or how clinicians should select patients. It also does not report study findings showing that testing or intervention at this stage prevents disease or improves outcomes.
It remains unclear from the excerpt what specific prevention or treatment options Chin considers appropriate for people with SCD, or when a clinician should recommend biomarkers. The cause of an individual’s symptoms can only be assessed in the context of their health, history and examination.
Evaluation and Follow-Up Steps
For someone experiencing persistent changes, the approach described by Chin is to discuss them with a qualified clinician, consider a thorough cognitive assessment and review potential contributors such as sleep, mood, medication and hearing. With the patient’s agreement, input from a family member or another person familiar with their usual abilities may help describe whether a change is continuing. Repeat testing can then provide a comparison over time.
For selected patients, clinicians may also discuss whether Alzheimer’s-related biomarker testing is relevant. The supplied material does not set out a timetable, eligibility criteria or a particular next milestone. Further guidance on how biomarkers should inform care, and whether early identification changes outcomes, is not established in the excerpt.
Key Questions
What is subjective cognitive decline?
SCD is a persistent personal sense that memory or thinking has worsened from an earlier level, even though comprehensive testing does not show objective impairment. It describes a concern, not its cause.
Does subjective cognitive decline mean someone has Alzheimer’s?
No. SCD is not an Alzheimer’s diagnosis. Sleep, medications, mood, medical conditions, hearing loss, stress and normal aging can also affect how a person experiences their thinking.
Why might normal test results not settle the concern?
Tests often compare a person with others of a similar age, not with their own earlier abilities. A person may have declined from a higher starting point and still score within the average range. Repeat testing can help track whether changes continue.
What does “SCD plus” mean?
It refers to features that may prompt closer attention, such as recent memory-focused changes, persistence, worry, seeking medical help or confirmation from someone familiar with the person. These features do not prove Alzheimer’s.
Can biomarkers identify Alzheimer’s before impairment?
Chin’s article names blood biomarkers, cerebrospinal fluid testing and amyloid PET as options for selected patients to investigate Alzheimer’s-related biology. The supplied excerpt does not explain who should receive them or what a result means for treatment, so those questions require discussion with a qualified clinician.
Source: beingpatient.com
